Peptides MOC
Scope: P1 peptide hub notes + core mechanism notes. Built from Gemini deep research corpus + PeptideDosages.com (2026-03-20). Batch A compounds (TB-500, Tesamorelin, CJC-1295 Ipamorelin, XW4475) added 2026-03-21. Batch C compounds (Glutathione, MOTS-c, PCC1, Fisetin) added 2026-03-21.
Peptide Hub Notes
| Peptide | Class | Status | Priority |
|---|---|---|---|
| Cagrilintide | Long-acting amylin analog (DACRA); AMY1/3 + calcitonin receptor agonist | Investigational (monotherapy NOT filed) | P1 — metabolic; monotherapy discontinued |
| CagriSema | Amylin (cagrilintide) + GLP-1 (semaglutide) dual agonist | Investigational (filed, not approved) | P1 — metabolic; additivity confirmed |
| Retatrutide | Triple GLP-1/GIP/Glucagon agonist | Research-only (Phase 3) | P1 — metabolic anchor |
| Survodutide | Dual GLP-1/GCGR agonist (BI 456906); once-weekly SC | Investigational (Phase 3 SYNCHRONIZE; filing expected early 2026) | P1 — metabolic; GCGR energy-expenditure axis; MASH signal |
| Mazdutide | Dual GLP-1/GCGR agonist (IBI-362 / LY3305677); once-weekly SC | NMPA-approved (China only); no FDA/EMA approval | P1 — metabolic; GLORY-1 phase 3 in Chinese adults; no non-Chinese phase 3 data; no head-to-head vs other GLP-1 agents |
| BPC-157 | Tissue repair pentadecapeptide | Research-only · human evidence limited | P1 — structural repair |
| GHK-Cu | Copper tripeptide / genomic remodeler | OTC topical; grey inj. | P1 — ECM, longevity |
| SLU-PP-332 | ERR pan-agonist / exercise mimetic | Preclinical | P1 — endurance pillar |
| Melanotan II PT-141 | Melanocortin pan-agonist | MT-II: research; PT-141: FDA approved | P1 — sexual health + metabolic |
| Noopept Semax Selank | Nootropic regulatory peptides | Rx in Russia; grey US | P1 — neurocognitive |
| TB-500 | Thymosin Beta-4 fragment / actin sequestrant | Research-only · WADA banned | P1 — systemic repair |
| Tesamorelin | GHRH analog | FDA approved (HIV lipodystrophy); off-label | P1 — somatotropic axis |
| CJC-1295 Ipamorelin | GHRH + GHSR agonist stack | Research-only · FDA Category 2 · WADA banned | P1 — GH pulse amplification |
| XW4475 | CRF2 receptor agonist (UCN2 analog) | Preclinical | P1 — body recomposition |
| Epithalon | Telomerase activator / pineal tetrapeptide | Research-only | P1 — telomere longevity |
| Glutathione | Endogenous antioxidant tripeptide | OTC (oral/liposomal) | P1 — redox foundation |
| Follistatin Gene Therapy FST-344 | AAV1/minicircle gene therapy; myostatin antagonist + mTOR activator | Research-only — NOT FDA-approved; no healthy-adult trial data; male-only; oxidative capacity trade-off | Investigational — muscle (degenerative disease context only) |
| Myostatin-Follistatin Axis | TGF-β family muscle preservation axis; myostatin (GDF8), activin A, follistatin, ActRII blockade; mass-without-function evidence pattern across all drug programs | No FDA/EMA-approved agent; apitegromab nearest to approval; bimagrumab + GLP-1 fastest-moving frontier | P1 — muscle preservation mechanism hub |
| MOTS-c | Mitochondrial-derived peptide (MDP) | Research-only · WADA banned · FDA Cat. 2 | P1 — AMPK exercise mimetic |
| PCC1 | Senolytic polyphenol (trimeric procyanidin) | Research-only | P1 — senolytic anchor |
| Fisetin | Flavonoid (flavonol) senolytic/neuroprotectant | OTC | P1 — senolytic + neuroprotection |
| IGF-1 LR3 | Synthetic IGF-1 analog; reduced IGFBP binding; research-only; WADA S2 prohibited; no human LR3 trials; cancer/hypoglycemia risks | Research-only · WADA S2 · no FDA approval | P1 — somatotropic axis (safety anchor) |
Mechanism Notes
| Mechanism | Peptides/Compounds Involved |
|---|---|
| GLP-1 GIP Glucagon | Retatrutide, Ecnoglutide, Tirzepatide |
| Tissue Repair | BPC-157, GHK-Cu, TB-500 |
| Genomic Remodeling | GHK-Cu |
| Exercise Mimetics | SLU-PP-332, XW4475, MOTS-c |
| CRF2 receptor | XW4475 |
| Senolytic mechanisms | PCC1, Fisetin, Dasatinib+Quercetin |
Cross-Cutting Stacks
Metabolic Resurrection Stack
- Anchor: Retatrutide (GLP-1/GIP/Glucagon — fat obliteration)
- Muscle: SLU-PP-332 (ERR agonism — endurance + fat oxidation) + Melanotan II PT-141 (MC4R — appetite via separate axis)
- Skin protection: GHK-Cu (prevents GLP-1-induced skin laxity)
- Tissue repair: BPC-157 (angiogenesis + GHR upregulation)
Wolverine Stack
- BPC-157 TB-500 Combination Recovery — research-only injury repair combination; BPC-157 builds local angiogenesis/structure (animal evidence); TB-500 recruits repair cells systemically; human efficacy unproven; TB-500 has documented positive WADA doping cases; see BPC-157 TB-500 Combination Recovery for full evidence ceiling and NSAID co-use counseling gap
GH Amplification Stack
- Tesamorelin + CJC-1295 Ipamorelin — dual-axis somatotropic activation: GHRH (tesamorelin) + GHSR (ipamorelin); larger more robust GH pulses than either alone
Ultimate Recomposition Stack
- Retatrutide + XW4475 — Retatrutide drives extreme catabolism (GLP-1/GIP/Glucagon); XW4475 provides chemical anabolism (CRF2 → mTORC1); simultaneously protects myocardium from catabolic stress
Anabolic Recovery
- BPC-157 + CJC-1295 Ipamorelin — BPC-157 may upregulate GHR (in vitro/ex vivo signal); CJC-1295/Ipamorelin amplifies GH pulses; mechanistic rationale only — human efficacy for this combination is unstudied
Anti-Sarcopenia Stack
- Retatrutide + TB-500 — counters 25–45% lean mass loss during GLP-1-driven weight reduction
- Protein Intake GLP-1 Glucagon — protein intake protocol (1.8–2.2 g/kg actual body weight), DXA monitoring, BUN/urea compliance check; see mTOR AMPK Muscle Catabolism for mechanism
- Retatrutide Lean Mass Preservation — retatrutide-specific lean mass preservation protocol: protein targets, training cadence, BIA/DXA monitoring, catabolism signals; all retatrutide protein and training recommendations are extrapolated (no retatrutide-specific RCT)
- Follistatin Gene Therapy FST-344 ⚠️ — NOT actionable for healthy adults; no peer-reviewed human trial in healthy populations; all evidence in degenerative muscle disease; oxidative capacity trade-off confirmed in preclinical models; investigational only; see hub note for full evidence ceiling and anti-hype framing
Hypertrophy Safety Stack
- XW4475 + TB-500 — rapid mTOR-driven hypertrophy outpaces connective tissue/microvascular development; TB-500 ensures angiogenesis + fibroblast migration keeps pace
Neuro-Somatic Recovery
- BPC-157 + Noopept Semax Selank — BPC-157 mechanistic CNS claims are preclinical; Noopept/Semax/Selank is a nootropic stack with Russian approval; human TBI efficacy for BPC-157 is unestablished
Senolytic Regeneration Stack
- Senolytic phase: PCC1 or Fisetin — clears senescent cell burden (pulsed, intermittent)
- NAD+ support: NMN NAD+ — post-clearance NAD restoration (CD38+ senescent cells removed)
- ROS buffering: Glutathione — protects bystander cells during SASP/ROS burst from lysed senescent cells
- Tissue remodeling: GHK-Cu — replaces cleared cells with organized ECM infrastructure
- Prevention: Retatrutide — metabolic optimization prevents new senescent cell accumulation
- Note: Continuous low-dose fisetin (500 mg/day) acts as senomorphic (SASP suppression) rather than senolytic — appropriate for maintenance, not clearance
Interaction Notes
- Cannabis peptide interactions — goal conflict with Retatrutide; others negligible
Status Key
- Research-only: Not FDA approved; grey market / compounding required
- OTC: Available without prescription
- FDA approved: Has a labeled Rx indication
- Preclinical: Animal data only; no human trials
Source: Gemini Deep Research corpus + PeptideDosages.com (verified 2026-03-20) · Batch A added 2026-03-21 · Batch C added 2026-03-21 · BPC-157 upgraded to evidence-bounded hub 2026-03-28 (BATCH11)